Accendra Health holder to sell 10.7M shares

A 10% stockholder affiliated with Coliseum Capital plans a large Rule 144 resale of Accendra Health common shares through two brokers.

Rhea-AI Filing Summary

Accendra Health, Inc. (ACH) is the issuer for a planned resale of common stock disclosed by Coliseum Capital Management, LLC, a 10% stockholder, under Rule 144. Coliseum and an investment advisory client of Coliseum Capital Management together intend to sell up to 10,726,759 shares of Accendra Health common stock through JonesTrading Institutional Services LLC and Virtu Americas LLC.

The filing states an aggregate market value for the shares of $11,584,899.72 and notes that Accendra Health had 76,904,704 shares outstanding. The securities being sold were acquired in open market purchases made for cash, with acquisition dates commencing on July 31, 2024 and ceasing on August 14, 2025.

Key Figures

Shares to be sold: 10,726,759 shares Aggregate market value: $11,584,899.72 Shares outstanding: 76,904,704 shares +3 more

6 metrics

Shares to be sold 10,726,759 shares Common stock covered by the planned Rule 144 sale

Aggregate market value $11,584,899.72 Aggregate market value of Accendra Health common shares to be sold

Shares outstanding 76,904,704 shares Accendra Health common shares outstanding referenced in the filing

Planned sale date September 11, 2026 Approximate date of sale for the Rule 144 transaction

Acquisition period start July 31, 2024 Date purchases of the securities commenced

Acquisition period end August 14, 2025 Date purchases of the securities ceased

Key Terms

Rule 144, 10% Stockholder, investment adviser, separate account, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10% Stockholder regulatory

"In addition, information shall be given as to sales by all persons whose sales are required"

investment adviser financial

"for which Coliseum Capital Management, LLC ... serves as investment adviser and (b) a separate"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

separate account financial

"and (b) a separate account investment advisory client of CCM."

A separate account is a pool of investments legally kept apart from a firm’s general assets and managed specifically for a particular client, group of clients, or an insurance contract — like a dedicated suitcase of investments instead of putting everything in one closet. It matters to investors because it determines who absorbs gains or losses, usually offers protection from the firm’s creditors, and can have different fees, liquidity and rules than the firm’s main asset pool.

open market purchases market

"Open Market Purchases. Please refer to explanatory notes under "Remarks" below."

Open market purchases are buys of a company’s shares (or other securities) made on public exchanges at prevailing market prices rather than through private deals. For investors this matters because when a company buys back its own stock it reduces the number of shares available, which can boost per-share earnings and often signals management’s confidence; it also affects supply, demand and short-term liquidity much like someone quietly buying up items from a crowded marketplace.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Accendra Health (ACH)?

It discloses that a 10% stockholder affiliated with Coliseum Capital Management, LLC plans to sell up to 10,726,759 shares of Accendra Health common stock under Rule 144 through two brokerage firms.

How many Accendra Health (ACH) shares are planned to be sold under this Form 144?

The notice covers a proposed sale of up to 10,726,759 shares of Accendra Health common stock, according to the securities information and securities-to-be-sold sections.

What is the aggregate market value of the Accendra Health (ACH) shares in the Form 144?

The filing states an aggregate market value of approximately $11,584,899.72 for the Accendra Health common shares covered by the planned Rule 144 sale.

How many Accendra Health (ACH) shares were outstanding as referenced in the Form 144?

The Form 144 notes that there were 76,904,704 shares outstanding of Accendra Health common stock, providing context for the size of the planned resale.

Over what period were the Accendra Health (ACH) shares to be sold originally acquired?

The shares were acquired through open market purchases for cash, with purchases commencing on July 31, 2024 and ceasing on August 14, 2025, as stated in the remarks section.

Which brokers are involved in the planned Rule 144 sale of Accendra Health (ACH) shares?

The Form 144 lists JonesTrading Institutional Services LLC and Virtu Americas LLC as the brokers for the planned sale of the Accendra Health common stock on the NYSE.

Who is the selling security holder in the Accendra Health (ACH) Form 144?

The securities are held for the account of Coliseum Capital Partners, L.P. and a separate account client of Coliseum Capital Management, LLC, with Coliseum Capital Management acting as investment adviser.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:31 PM EDT Accepted by SEC EDGAR 09/11/2026 - 04:30 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001409751
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Accendra Health, Inc.
SEC File Number	001-09810
Address of Issuer	4435 Waterfront Drive Suite 300 Glen Allen VIRGINIA 23060
Phone	804-277-4304
Name of Person for Whose Account the Securities are To Be Sold	Coliseum Capital Management, LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	JonesTrading Institutional Services LLC 555 Saint Charles Drive Thousand Oaks CA 91360	10726759	11584899.72	76904704	09/11/2026	NYSE
Common Stock	Virtu Americas LLC 1633 Broadway New York NY 10019	10726759	11584899.72	76904704	09/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/31/2024	Open Market Purchases. Please refer to explanatory notes under "Remarks" below.	Open Market Purchases. Please refer to explanatory notes under "Remarks" below.			10726759	07/31/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities referred to in this Form 144 are held directly by (a) Coliseum Capital Partners, L.P., an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser and (b) a separate account investment advisory client of CCM. Christopher Shackelton and Adam Gray are managers of and have an ownership interest in each of CCM and CC. Regarding the "Securities To Be Sold" table, the dates of acquisition and dates of payment varied, with purchases commencing on July 31, 2024 and ceasing on August 14, 2025.
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Chivonne Cassar, as Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)